Advertisement

Extending adjuvant-temozolomide does not necessarily improve survival in patients with newly-diagnosed glioblastoma: a fifthteen-year territory-wide multi-centre retrospective cohort study

      Background: First-line treatment for glioblastoma after surgery consists of concurrent chemo-radiation (CCRT) followed by 6 cycles of adjuvant-temozolomide. This study investigates the association between the duration of adjuvant-temozolomide and overall survival (OS) in glioblastoma patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect